title: Methods for the expression, purification, preparation, and biophysical characterization of constructs of the c-Myc and Max b-HLH-LZs.
abstract: Specific heterodimerization and DNA binding by the b-HLH-LZ transcription factors c-Myc and Max is central to the activation and repression activities of c-Myc that lead to cell growth, proliferation, and tumorigenesis (Adhikary and Eilers, Nat Rev Mol Cell Biol 6:635-645, 2005; Eilers and Eisenman, Genes Dev 22:2755-2766, 2008; Grandori et al., Annu Rev Cell Dev Biol 16:653-699, 2000; Whitfield and Soucek, Cell Mol Life Sci 69:931-934, 2011). Although many c-Myc-interacting partner proteins are known to interact through their HLH domain (Adhikary and Eilers, Nat Rev Mol Cell Biol 6:635-645, 2005), current knowledge regarding the structure and the determinants of molecular recognition of these complexes is still very limited. Moreover, recent advances in the development and use of b-HLH-LZ dominant negatives (Soucek et al., Nature 455:679-683, 2008) and inhibitors of c-Myc interaction with its protein partners (Bidwell et al., J Control Release 135:2-10, 2009; Mustata et al., J Med Chem 52:1247-1250, 2009; Prochownik and Vogt, Genes Cancer 1:650-659, 2010) or DNA highlight the importance of efficient protocols to prepare such constructs and variants. Here, we provide methods to produce and purify high quantities of pure and untagged b-HLH-LZ constructs of c-Myc and Max as well as specific c-Myc/Max heterodimers for their biophysical and structural characterization by CD, NMR, or crystallography. Moreover, biochemical methods to analyze the homodimers and heterodimers as well as DNA binding of these constructs by native electrophoresis are presented. In addition to enable the investigation of the c-Myc/Max b-HLH-LZ complexes, the protocols described herein can be applied to the biochemical characterization of various mutants of either partner, as well as to ternary complexes with other partner proteins.
authors.affiliation: Département de Pharmacologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
authors.forename: Marie-Eve
authors.initials: ME
authors.lastname: Beaulieu
authors.forename: François-Olivier
authors.initials: FO
authors.lastname: McDuff
authors.forename: Mikaël
authors.initials: M
authors.lastname: Bédard
authors.forename: Martin
authors.initials: M
authors.lastname: Montagne
authors.forename: Pierre
authors.initials: P
authors.lastname: Lavigne
mesh_terms: D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000737:chemistry / Q000302:isolation & purification / Q000502:physiology; D050976:Basic-Leucine Zipper Transcription Factors / Q000737:chemistry / Q000302:isolation & purification / Q000502:physiology*; D004247:DNA / Q000378:metabolism; D024202:Electrophoretic Mobility Shift Assay / Q000379:methods; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics*; D011485:Protein Binding; D055503:Protein Multimerization; D016271:Proto-Oncogene Proteins c-myc / Q000737:chemistry / Q000302:isolation & purification / Q000502:physiology*
chemical_list: D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; D050976:Basic-Leucine Zipper Transcription Factors; C067850:Myc associated factor X; D016271:Proto-Oncogene Proteins c-myc; D004247:DNA